Joshua Webster - Distinguished Scientist (Pathology-Collaborative), Pathology

Joshua Webster

Distinguished Scientist (Pathology-Collaborative), Pathology

"Pathologic evaluations can provide unique insights into the mechanisms of disease and the phenotypic consequences of molecular alterations that impact both basic discovery and drug development."
10
Years at Genentech
7
Awards & Honors

While receiving my doctorate of veterinary medicine at Michigan State University, I became increasingly interested in understanding the pathogenesis and mechanisms of disease. This interest led me to complete a Ph.D. focused on the characterization of prognostic biomarkers for canine cutaneous mast cell tumors, a common, but clinically heterogeneous form of skin cancer in dogs. Following my Ph.D. I completed a residency in anatomic pathology at Purdue University and subsequently became boarded by the American College of Veterinary Pathologists. I then continued to pursue my interest in investigative pathology by accepting a position as a staff scientist in the Molecular Pathology Unit of the Laboratory of Cancer Biology and Genetics at the National Cancer Institute. In this position, I served as a collaborative pathologist where I incorporated both traditional interpretative light microscopy and image analysis-based quantitative analyses to support basic scientific research at the NCI. In 2012, I jumped at the opportunity to join the Research Pathology group at Genentech, where I support early discovery and Immunology programs, and oversee the microscopy and digital pathology core laboratories within Pathology.

Featured Publication

RIPK1 inhibits ZBP1-driven necroptosis during development.

Nature. 2016 Dec 1;540(7631):129-133.

Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, Lill JR, Roose-Girma M, Warming S, Solon M, Ngu H, Webster JD, Dixit VM.